Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Observer-blind, Phase 2 Study to Evaluate Safety and Immunogenicity of the Investigational M72/AS01E Mycobacterium Tuberculosis (Mtb) Vaccine in Virally Suppressed, Antiretroviral-treated Participants With Human Immunodeficiency Virus (HIV)

NCT04556981 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT04556981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04556981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Observer-blind, Phase 2 Study to Evaluate Safety and Immunogenicity of the Investigational M72/AS01E Mycobacterium Tuberculosis (Mtb) Vaccine in Virally Suppressed, Antiretroviral-treated Participants With Human Immunodeficiency Virus (HIV)
Lead sponsor
Gates Medical Research Institute
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2020
Completion date
August 12, 2022
Enrollment
402 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus